A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia

The therapeutic approach to chronic myeloid leukaemia (CML) has changed in recent years. As a result, a high percentage of current patients in the chronic phase of the disease almost have an average life expectancy. Treatment also aims to achieve a stable deep molecular response (DMR) that might all...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín Roldán, Alicia, Sánchez Suárez, María Del Mar, Alarcón-Payer, Carolina, Jiménez Morales, Alberto, Puerta Puerta, José Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222180/
https://www.ncbi.nlm.nih.gov/pubmed/37242605
http://dx.doi.org/10.3390/pharmaceutics15051363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222180/
https://www.ncbi.nlm.nih.gov/pubmed/37242605
http://dx.doi.org/10.3390/pharmaceutics15051363

Ejemplares similares